跳到正文
原文
Medical Xpress·· 2 天前精选AI 评分67

香港20年队列研究:氯氮平相关中性粒细胞减少风险在前18周最高、两年后趋于平稳

First evidence from a Chinese population supports review of long-term blood monitoring for local clozapine use

AI 导读

香港大学精神医学科Sherry Chan Kit-wa教授团队发表在英国精神病学杂志的一项观察性研究显示,氯氮平相关中性粒细胞减少的风险在治疗最初18周内最高并随时间逐步下降。

推荐理由

香港大学团队基于20年全港健康记录数据的观察性研究显示氯氮平相关中性粒细胞减少风险随时间递减,为调整本地长期血检要求提供首个大规模华人人群证据。

正文
HKUMed research provides first evidence from a Chinese population to support review of long-term blood-monitoring for local clozapine use
Led by professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong's long-term blood monitoring requirements for clozapine use. Credit: The University of Hong Kong

An international research team led by the Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has completed a long-term population-based research study to improve care for people with treatment-resistant schizophrenia (TRS), the most severe form of this mental health condition. The findings reinforce the importance of timely access to clozapine and provide the first large-scale evidence from a Chinese population to support a review of Hong Kong's long-term blood monitoring requirements.

Currently, the requirements mandate monthly blood tests while patients are taking clozapine according to the existing guideline, which can impose a substantial burden on patients, their families and clinical services. The study was published in The British Journal of Psychiatry.

Clozapine is the only antipsychotic approved by the U.S. Food and Drug Administration specifically for TRS. While highly effective, concerns about neutropenia, a reduction in infection-fighting white blood cells, necessitate regular blood testing. In this HKUMed-led study, researchers examined 20 years of Hong Kong health record data between 2003 and 2019, with follow-up until 2023. It compared data from 4,868 people who started clozapine with that of 38,277 people receiving other second-generation antipsychotics.

The study found that the risk of clozapine-associated neutropenia was highest during the first 18 weeks of treatment and progressively decreased over time. After approximately two years, the risk profile was comparable to that of people receiving non-clozapine second-generation antipsychotics. The incidence of serious neutropenia was also very similar between the two groups.

Local evidence highlights optimal monitoring frequency

The findings support concentrated surveillance during early treatment: weekly neutrophil monitoring for the first 18 weeks, followed by monthly monitoring for up to two years. Thereafter, monitoring frequency could potentially align with that of non-clozapine second-generation antipsychotics. Any changes should be implemented only through a formal review of Hong Kong's clinical guidance, in alignment with evolving international standards, individual clinical assessment and appropriate safeguards.

Professor Sherry Chan Kit-wa, Department of Psychiatry, School of Clinical Medicine, HKUMed, and corresponding author of the study, said, "For people with TRS, clozapine can be life-changing, but the burden of monthly blood tests while taking the medication can discourage some patients from starting or continuing treatment. Our findings provide an evidence base for a careful, clinically led review of how long-term monitoring can be made safer, more proportionate and less burdensome."

The study also found that risk patterns varied by age and sex, suggesting that a personalized monitoring approach may be more appropriate than a one-size-fits-all model. The researchers stressed that patients should always consult their health care providers before making any changes to their medication or blood-testing schedules.

A sustained research program on patient-centered outcomes

This monitoring study builds on two large-scale Hong Kong studies as part of the same research program. In an 18-year population-based study of 9,456 people with schizophrenia, researchers found that continuous clozapine use was associated with a lower risk of suicide mortality and all-cause mortality than continuous treatment with other antipsychotics even after accounting for the use of additional antipsychotic medications. The findings were published in The British Journal of Psychiatry.

In a separate 20-year self-controlled study published in Biological Psychiatry, researchers examined 4,794 people who began clozapine treatment. The study found that periods of clozapine use were associated with substantially lower psychiatric hospitalization risk than periods of treatment with other antipsychotics. The risk of psychiatric hospitalization was 79% lower during the first clozapine treatment period and 73% lower during subsequent clozapine treatment periods. By comparing medication periods for the same individual, the study reduced the influence of interpatient variability on the results.

Professor Chan said, "Taken together, these studies provide a more complete picture of both the benefits and risks of clozapine treatment. While careful monitoring remains important, the evidence suggests that clozapine can offer substantial benefits for people with TRS. We hope these findings will help reduce avoidable barriers to treatment, support informed decision-making between patients and health care professionals and ultimately improve the quality of care for patients."

The researchers emphasized that these observational studies demonstrate associations rather than definitively establishing that clozapine directly caused the observed outcomes. Nevertheless, the large territory-wide datasets, long follow-up periods and complementary study designs provide important real-world evidence for patients and clinicians in Hong Kong.

Publication details

Huiquan Zhou et al., Incidence of clozapine-associated neutropenia in patients with schizophrenia: 20-year population-based study in Hong Kong, The British Journal of Psychiatry (2026). DOI: 10.1192/bjp.2026.10726

Journal information: British Journal of Psychiatry , Biological Psychiatry

Key medical concepts

Clozapine

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: First evidence from a Chinese population supports review of long-term blood monitoring for local clozapine use (2026, November 17) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-evidence-chinese-population-term-blood.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com